USA flag logo/image

An Official Website of the United States Government

Development Of An Eye Drop To Treat Presbyopia

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43EY022817
Solicitation Year:
2012
Solicitation Topic Code:
NEI
Solicitation Number:
PA11-096
Small Business Information
ENCORE VISION, INC.
1120 South Freeway, Suite 118 Fort Worth, TX 76104-5064
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Development Of An Eye Drop To Treat Presbyopia
Agency: HHS
Contract: 1R43EY022817-01
Award Amount: $150,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Encore Vision has identified an innovative treatment for Presbyopia. The aim of the proposed phase I studies is to develop a topical ocular formulation of our co-drug to achieve therapeutic levels of active agent in therabbit aqueous humor without adversely affecting cornea health and lens metabolism. Onset of Presbyopia leading to progressive loss of near vision after age of 40 presents with limited treatment options including eyeglasses, contact lenses, or Lasik surgery. According to Encore Vision s working hypothesis, the age-dependent increase in protein sulfhydryl group oxidation (PSH to PSSR and PSSP) to form protein cross-links contributes to the age-dependent decrease in lens elasticity underlying the loss of accommodative amplitude. We have identified a proprietary amphipathic co-drug that restores the elasticity of the lens when applied topically to the eyes of 8-month-old mice. The co-drug elicits no acute toxicology in Draize testing in rabbits. The co-drug iscleaved by cellular esterases to release a pro-reductant, that when converted to active reducing agent by cellular oxidoreductases, increases mouse lens elasticity by decreasing the number of protein-disulfide bonds. The reducing agent is methylated for clearance in vivo. Oxidoreductase-dependent reduction of the pro-reducing agent requires energy-dependent maintenance of the redox balance with NAD+, NADH and NADP+, NADPH. The route for clearance of excess reducing agent uses S-adenosylmethionine (SAM) asthe methyl donor. Therefore topical treatment with pro-reductant could potentially cause an energy drain as well as a reduction in SAM levels that in turn could affect other critical metabolic processes in the cornea and lens. The esterase-dependent cleavage of the co-drug also releases an intermediate to regenerate SAM. Our phase-I Specific Aim is to develop a formulation of our co-drug that ensures cornea health while preventing adverse changes in redox balance and SAM-dependent methylation potential in the lens. To achieve our aim we will complete the following tasks: Task 1. Using rabbits, determine, the effects topical ocular doses of our co-drug formulation on cornea barrier function (Fluorescein) and cornea thickness (pachymetry). If permanent changesin cornea health are observed, lower dose formulations will be prepared and tested; Task 2. Determine the ocular pharmacokinetics of our co-drug, its metabolites, SAM-cycle intermediates and redox balance. For task 2, cornea perfusion and lens culture will be used to define corneal and lenticular pharmacokinetics that will then be compared to aqueous humor levels after topical ocular dosing of rabbits. PUBLIC HEALTH RELEVANCE: Onset of Presbyopia, the progressive loss of near vision after age of 40, presents with limited treatment options including eyeglasses, contact lenses, or Lasik surgery. Encore Vision's goal is to develop a safe topical ocular drop as an option for the treatment of presbyopia.

Principal Investigator:

William H. Garner
817-945-3391
dr_garner@msn.com

Business Contact:

William R. Burns
817-945-3391
wburns@encorevisioninc.com
Small Business Information at Submission:

ENCORE VISION, INC.
1120 South Freeway, Suite 118 Fort Worth, TX 76104-5064

EIN/Tax ID: 120852274
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No